pharmaand
specialty pharma / commercial-stage oncology products
Privately held: no public share price · Austria
Assets
(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Type I interferon receptor | Chronic Hepatitis B | |
| Approved | PARP (poly ADP-ribose polymerase) enzymes, PARP1/2Small molecule | Metastatic Castration-Resistant Prostate CancerOvarian CancerProstate Cancer | |
| US approval withdrawn | HDACSmall molecule | Multiple Myeloma |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.